136 related articles for article (PubMed ID: 28667460)
21. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiology of the aging kidney.
Gilbert BR; Vaughan ED
Clin Geriatr Med; 1990 Feb; 6(1):13-30. PubMed ID: 2405974
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
25. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
[TBL] [Abstract][Full Text] [Related]
26. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.
Scotcher D; Jones CR; Galetin A; Rostami-Hodjegan A
J Pharmacol Exp Ther; 2017 Mar; 360(3):484-495. PubMed ID: 28057840
[TBL] [Abstract][Full Text] [Related]
27. Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.
Gonzalez M; Goracci L; Cruciani G; Poggesi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1397-408. PubMed ID: 25219632
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Hariharan S; Madabushi R
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):119S-25S. PubMed ID: 21956605
[TBL] [Abstract][Full Text] [Related]
29. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance.
Axelsson J; Bergsten A; Qureshi AR; Heimbürger O; Bárány P; Lönnqvist F; Lindholm B; Nordfors L; Alvestrand A; Stenvinkel P
Kidney Int; 2006 Feb; 69(3):596-604. PubMed ID: 16395259
[TBL] [Abstract][Full Text] [Related]
30. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function.
Spruill WJ; Wade WE; Cobb HH
Am J Geriatr Pharmacother; 2008 Aug; 6(3):153-60. PubMed ID: 18775390
[TBL] [Abstract][Full Text] [Related]
31. Use of estimated glomerular filtration rate for drug dosing in the chronic kidney disease patient.
Hudson JQ; Nyman HA
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):482-91. PubMed ID: 21709552
[TBL] [Abstract][Full Text] [Related]
32. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.
Yin OQ; Merante D; Truitt K; Miller R
J Clin Pharmacol; 2016 Feb; 56(2):203-12. PubMed ID: 26138993
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
Martin JL; Esmaeili H; Manuel RC; Petrini M; Wiebe S; Maas H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):399-406. PubMed ID: 29695165
[TBL] [Abstract][Full Text] [Related]
35. Estimation of glomerular filtration rate from the serum creatinine concentration.
Smith SA
Postgrad Med J; 1988 Mar; 64(749):204-8. PubMed ID: 3174538
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
37. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
38. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
39. Design and conduct considerations for studies in patients with impaired renal function.
Ravenstijn P; Chetty M; Manchandani P
Clin Transl Sci; 2021 Sep; 14(5):1689-1704. PubMed ID: 33982447
[TBL] [Abstract][Full Text] [Related]
40. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D
Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
